Research Analysts Set Expectations for Oculis Q2 Earnings

Oculis Holding AG (NASDAQ:OCS) – Stock analysts at HC Wainwright dropped their Q2 2025 EPS estimates for Oculis in a research note issued on Monday, May 12th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.47) per share for the quarter, down from their prior estimate of ($0.41). HC Wainwright currently has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis’ Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($2.20) EPS and FY2026 earnings at ($1.69) EPS.

Several other brokerages have also recently weighed in on OCS. Robert W. Baird boosted their price objective on shares of Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research note on Thursday, March 13th. Chardan Capital boosted their price objective on shares of Oculis from $28.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, May 9th.

Oculis Stock Performance

NASDAQ OCS opened at $17.76 on Wednesday. The firm’s fifty day moving average price is $17.99 and its two-hundred day moving average price is $18.40. The stock has a market cap of $775.44 million, a PE ratio of -9.20 and a beta of 0.27. Oculis has a fifty-two week low of $10.79 and a fifty-two week high of $23.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02.

Oculis (NASDAQ:OCS) last posted its earnings results on Thursday, May 8th. The company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.26). The company had revenue of $0.32 million for the quarter, compared to the consensus estimate of $0.22 million. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%.

Institutional Trading of Oculis

Several institutional investors have recently modified their holdings of OCS. SR One Capital Management LP bought a new stake in shares of Oculis in the first quarter worth $6,137,000. Aberdeen Group plc boosted its position in Oculis by 24.1% during the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company’s stock valued at $23,847,000 after acquiring an additional 243,695 shares during the last quarter. abrdn plc boosted its position in Oculis by 23.0% during the fourth quarter. abrdn plc now owns 1,009,424 shares of the company’s stock valued at $17,150,000 after acquiring an additional 188,871 shares during the last quarter. Citadel Advisors LLC bought a new stake in Oculis during the fourth quarter valued at $389,000. Finally, XTX Topco Ltd bought a new stake in Oculis during the fourth quarter valued at $225,000. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.